In brief
The FDA's approval of a generic version of mifepristone by Evita Solutions is stirring controversy as anti-abortion groups push back against the decision. Health officials, including Secretary Robert F. Kennedy Jr., have faced mounting pressure to reassess the drug's safety. Mifepristone, which has been deemed safe and effective for over two decades, is often used in combination with misoprostol for abortions. However, state laws impose significant restrictions on its access, impacting many potential users. The approval process for generic medications typically follows patent expirations, leading to quick approvals once applications are submitted.
WASHINGTON (AP) — Federal officials have approved another generic version of the abortion pill mifepristone, a regulatory formality that quickly triggered pushback from anti-abortion groups aligned with the Trump administration. Drugmaker Evita Solutions announced on its website that the Food and Drug Administration signed off on its low-cost form of the pill, which is approved to end pregnancies through 10 weeks. Students for Life Action, an anti-abortion organization, criticized the approval, calling it 'a stain on the Trump presidency.' The backlash has escalated as Republican President Donald Trump's health officials face mounting pressure from abortion opponents to reevaluate mifepristone, which has long been endorsed as safe by FDA scientists. In a response to growing concerns, Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary pledged to conduct a thorough review of the drug’s safety. Mifepristone was first approved by the FDA in 2000, with the first generic version launched by GenBioPro in 2019, and the recent approval follows a trend of increasing access to abortion medication. The FDA's review process for generic drugs typically spans around ten months; however, Evita Solutions submitted its application four years ago, reflecting the complexities surrounding access to such medications. Amid ongoing legal challenges and state-level restrictions, the approval of a second generic version is unlikely to widen access significantly, particularly as many states impose bans or various restrictions on abortion-related services.
